Overview of Afonilum SR

Quick Facts

Property	Description
Active ingredient	Choline Theophyllinate (Oxtriphylline)
Form	Controlled-Release Tablet (SR)
Pharmacological class	Bronchodilator, Xanthine Derivative
Common use	Alleviating airway obstruction and breathing difficulty
Origin	Synthetic Salt

What Type of Medicine is Afonilum SR (Choline Theophyllinate)?

Afonilum SR is a systemic pharmaceutical agent classified as a bronchodilator utilized to manage breathing issues linked to airway obstruction. The medicine belongs to the Xanthine Derivatives pharmacological class, with its core activity provided by the compound Choline Theophyllinate, which is also recognized as Oxtriphylline. This compound is administered orally to exert its effects across the respiratory system, targeting the underlying muscle tension. The drug is clinically recognized for its ability to ease muscle constriction.

Composition and Origin: The Salt Form

The composition of Afonilum SR is defined by its active ingredient, Choline Theophyllinate, a synthetic salt derived from the well-established theophylline moiety bound to choline. The addition of choline stabilizes the active component, yielding a reliable and soluble compound. The distinguishing SR designation specifies the medicine is a Sustained-Release or Controlled-Release oral tablet. This specialized dosage form is critical for its therapeutic profile, as it guarantees the gradual and continuous release of Choline Theophyllinate over an extended duration. This design is key for maintaining therapeutic stability and ensuring a more consistent effect throughout the dosing interval.

What is the General Purpose of Afonilum SR?

The primary purpose of Afonilum SR is to function as a respiratory smooth muscle relaxant, directly counteracting the constriction that impedes airflow in the lungs. By acting as an adenosine receptor antagonist and inhibiting specific enzymes, the drug promotes the widening of the bronchial tubes. This mechanism directly alleviates the general sensation of chest tightness and difficulty associated with obstructed air movement, promoting overall respiratory comfort.

What side effects are possible with Afonilum SR?

Possible Side Effects and Safety Information

The safety profile of Afonilum SR (Choline Theophyllinate), a xanthine derivative, is organized by regulatory agencies based on System-Organ Classes (SOC) and is highly dependent on the amount of medicine present in the bloodstream. The occurrence and severity of many adverse reactions typically increase if the plasma concentration exceeds recommended limits.

Documented Adverse Reactions and Frequencies

Adverse reactions are classified using standard regulatory frequency terms. Commonly documented reactions in official labeling, primarily affecting the nervous, cardiac, and gastrointestinal systems, include nausea, vomiting, headache, insomnia, tremor, dizziness, palpitations, and restlessness.

Serious Adverse Reactions

The regulatory profile explicitly lists serious adverse reactions, usually associated with toxicity, such as seizures (convulsions), severe cardiac arrhythmias, and potentially anaphylactic reactions. Acute toxicity may also lead to severe gastrointestinal effects like haematemesis (vomiting blood).

Safety Constraints and Special Populations

Official documents highlight safety constraints tied to pre-existing conditions. Caution is advised for patients with a history of peptic ulcers, seizure disorders, or certain cardiac arrhythmias. The medicine is typically contraindicated in individuals with known hypersensitivity to xanthine derivatives.

Specific patient populations are noted for increased risk. Elderly patients and those with hepatic impairment or Congestive Heart Failure (CHF) have an elevated risk of toxicity due to the possibility of reduced drug clearance. Furthermore, concomitant use with certain medications, such as some quinolone antibiotics, may significantly elevate the plasma levels of Choline Theophyllinate, increasing the potential for adverse effects.

Overdose and Emergency Response

Overdose and when to seek help: Afonilum SR (Choline Theophyllinate)

This section outlines the officially documented manifestations of overdose with Choline Theophyllinate and the required emergency actions, based strictly on government regulatory documents.

Documented Overdose Manifestations

Overdose may initially present with gastrointestinal disturbances (nausea, severe vomiting, abdominal pain) and neurological excitation (tremor, restlessness, insomnia, headache, agitation). The sustained-release nature of Afonilum SR may delay the onset of severe toxicity, often by 12 hours or more.

Severe and Life-Threatening Outcomes

Serious intoxication can rapidly progress to life-threatening cardioneurotoxicity. Documented severe outcomes include seizures (convulsions), ventricular arrhythmias (irregular heart rhythm), profound hypotension, and cardiac arrest. Significant metabolic changes, such as hypokalemia (low potassium) and hyperglycemia, are also officially documented.

Emergency Actions and Urgent Help

Immediate medical attention must be sought for any suspected overdose. Contact emergency services or a Poison Control Center right away, especially if severe symptoms like seizures or irregular heart rhythm occur. The official management procedures require symptomatic and supportive treatment, including continuous cardiac monitoring and correction of electrolyte abnormalities. Enhanced elimination procedures, such as multiple-dose oral activated charcoal, are often required, as no specific pharmacological antidote is known.

Chronic overdose and specific patient populations, including the elderly and very young infants, are documented as being more susceptible to severe toxicity at lower drug concentrations.

Therapeutic Uses of Afonilum SR

What Afonilum SR Treats: Main Uses and Benefits

The primary role of Afonilum SR is to provide supportive relief in the management of chronic conditions characterized by obstructive airway diseases. The medication is generally used for managing symptoms associated with established illnesses such as Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and asthma.

Symptom Relief and Therapeutic Context

Afonilum SR is relevant in contexts involving heightened systemic burden in these long-term illnesses, which generally assists with maintaining comfort and contributes to easing the overall symptom burden. It offers supportive symptomatic relief from the key physical manifestations of airway constriction, including pronounced wheezing, bothersome chest tightness, and acute shortness of breath (dyspnea).

The sustained-release format is particularly relevant for managing recurrent symptoms, especially nocturnal manifestations that tend to occur during sleep. The sustained effect is relevant for easing these nocturnal issues, which may help address symptoms that interfere with daily functioning and supports general well-being during symptomatic phases for improved comfort.

QuickFact Block

Quick Fact: Relief for Obstructive Symptoms
Symptom Domain	Airway Constriction (Wheezing, Chest Tightness, Dyspnea)
Use Context	Applied in clinical settings that involve recurrent symptom patterns
Key Benefit	Supports stability and comfort during symptomatic periods

Eligibility and Restrictions for Use

Who Can and Cannot Use Afonilum SR?

The eligibility for Afonilum SR (Choline Theophyllinate/Theophylline) is defined by official regulatory documents through absolute prohibitions and conditions that require caution.

Populations for Whom Use is Contraindicated Afonilum SR must not be used in patients with a documented hypersensitivity or allergy to theophylline, its components, or any other xanthine derivatives. Use is also strictly prohibited in patients with established coronary artery disease.

Restricted or Conditional Use Use requires extreme caution and close monitoring in several high-risk populations due to the potential for severe toxicity or condition exacerbation:

Organ Impairment: Patients with liver disease (such as cirrhosis or acute hepatitis) where drug clearance is significantly decreased.
Comorbidities: Individuals with seizure disorders, active peptic ulcer disease, or certain cardiovascular conditions like congestive heart failure.

Age and Pregnancy Rules

Older Adults: Patients over 60 years of age require extreme caution due to increased risk of toxicity.
Pediatric Use: Use in children younger than 1 year is generally not recommended due to greater susceptibility to side effects.
Pregnancy Status: The drug is classified as Pregnancy Category C and is used only when the potential benefit to the mother outweighs the potential risk to the fetus.

What should I know about interactions with other medicines?

The official interaction profile for Afonilum SR (Choline Theophyllinate) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. Certain combinations are strictly contraindicated, including co-administration with Riociguat and Febuxostat. Additionally, Ciprofloxacin use must be avoided due to the documented risk of serious and potentially fatal reactions.

The most common interaction mechanism involves the hepatic clearance of Afonilum SR, which is principally mediated by the cytochrome P450 enzyme CYP1A2. Inhibition of this enzyme by medicines like Fluvoxamine and Cimetidine is formally documented to increase plasma concentrations. Conversely, enzyme inducers such as Rifampicin and the herbal supplement St. John's Wort are documented to decrease drug exposure, which may reduce effectiveness.

Pharmacodynamic interactions include antagonism, where Theophylline decreases the therapeutic efficacy of Adenosine, and additive effects, such as the increased risk of hypokalemia when co-administered with sympathomimetic amines. Timing-based restrictions mandate that Afonilum SR should not be administered within 12 hours of other xanthine derivatives.

Furthermore, regulatory documentation notes that clearance is significantly reduced in populations with hepatic impairment and is altered by lifestyle factors like smoking status and high consumption of charbroiled meat or cruciferous vegetables.

Mechanism of Action

The active component of Afonilum SR, theophylline, modulates physiological functions through several distinct molecular mechanisms. The primary effect is achieved by acting as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes ( PDE3 and PDE4) in bronchial smooth muscle. This inhibition prevents the breakdown of cyclic adenosine monophosphate (cAMP), sustaining an intracellular signal that leads directly to the relaxation of the bronchial smooth muscle and the dilation of the bronchial tubes.

Simultaneously, theophylline acts as an antagonist of Adenosine Receptors ( A1 and A2 B), preventing the mediator adenosine from triggering bronchoconstriction and excessive cellular activation. This contributes to the modulation of airway responsiveness to activating stimuli. Additionally, theophylline influences processes within the respiratory system by restoring activity of the nuclear enzyme Histone Deacetylase 2 (HDAC2), which mediates the suppression of pro-inflammatory gene expression. The drug also mechanistically modifies the contractile dynamics of the diaphragm, influencing the primary muscle of respiration.

Dosage and Administration Information

How to Use Afonilum SR

The administration of Afonilum SR, a controlled-release formulation of Choline Theophyllinate (Oxtriphylline), is based on established protocols for the theophylline class.

Administration Scope

Parameter	General Administration Guidelines
Route of administration	Oral administration only.
Dosing schedule	The dose is individualized based on the patient’s status. Initial doses are low (e.g., 300–400 mg/day as anhydrous theophylline) and are progressively adjusted under medical supervision.
Timing in relation to meals	Can be taken with or without food; consistent daily timing relative to meals is emphasized.
Preparation requirements	The extended-release tablet or capsule must be swallowed whole. The product should not be broken, crushed, or chewed to preserve the controlled-release mechanism.
Age-group administration rules	Older adults (age 60 and over) often have a lower maximum daily dose (e.g., not more than 400 mg per day) due to altered drug clearance, and pediatric dosing is weight-based.
Missed-dose rules	If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. No extra or double dose should be taken.
Special procedural conditions	Dose adjustment and verification require Therapeutic Drug Monitoring (TDM)—periodic measurement of serum theophylline concentrations—during initiation and long-term maintenance.

Resulting Procedural Structure

The administration of Afonilum SR is structured around a once or twice daily dosing schedule designed for continuous maintenance therapy. The protocol requires the dose to be titrated and verified using TDM to establish the appropriate long-term regimen across all populations. The integrity of the oral tablet must be maintained, as crushing the controlled-release form is prohibited.

Recent Clinical Evidence

Research evidence / Overview of studies for Afonilum SR

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research examining the active component of Afonilum SR has included controlled clinical trials and broader systematic reviews. These studies primarily examined outcomes related to physical discomfort and systemic or functional imbalance, such as measuring changes in lung function tests (like FEV1) and observing patterns in blood oxygen and carbon dioxide levels. The research has focused on adults with conditions involving functional limitations, with studies often used in observational settings evaluating daily-life functioning.

Studies report how symptoms evolved in the observed populations, particularly noting changes in lung function measurements over short time intervals. Studies monitored patterns related to measurements of physiological strain or stress during the study period. Research described the monitoring of symptom intensity or variability, measuring outcomes related to physical discomfort.

Evidence for Use in Chronic Asthma

The use of Afonilum SR was studied for managing chronic asthma, a condition characterized by fluctuating or episodic manifestations. Research primarily used randomized clinical trials that monitored outcomes related to physical discomfort, such as tracking changes in breathing function and patient-reported outcomes describing perceived discomfort. The sustained-release formulation was used in trials assessing short-term or episodic symptom patterns, particularly those associated with nocturnal symptoms.

Studies explored the medicine’s use in both adults and children with asthma. Findings describe patterns observed in the studies related to lung function and symptom scores. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience during phases of heightened symptom activity. Data show patterns related to patient-reported outcomes describing daily functioning or activity level.

Long-Term Follow-up and Maintenance Studies

Research on Afonilum SR was evaluated in settings observing responses over defined time intervals. Follow-up durations were limited in many key trials, meaning there is limited information for long-term outcomes and the measurement of persistence of observed changes over time. Certainty remains low regarding the effects on clinical milestones tracked over many years.

Overall Evidence Consistency and Research Gaps

Comparative evidence against newer drug classes remains limited. The evidence quality varies across studies, with small sample sizes and limited follow-up durations being common research limitation frames. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. Evidence highlights what is known—and what is still uncertain—about the medicine's role within the current broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Afonilum SR (FAQ)

Q: What is the difference between Afonilum SR and regular (immediate-release) Afonilum?

A: Afonilum SR stands for sustained-release. This formulation is designed to release the active medicine slowly and continuously over a longer period, typically 12 to 24 hours. This sustained action is associated with less frequent dosing and helps maintain more consistent levels of the medicine in the bloodstream over the dosing interval. Regular, or immediate-release, Afonilum is absorbed quickly, with its peak concentration occurring much sooner.

Q: Is Afonilum SR similar to other xanthine-based medications?

A: Yes, the active ingredient in Afonilum SR, theophylline, is chemically categorized as a methylxanthine. This group of compounds includes other common substances like caffeine and the medication aminophylline. Due to this similar chemical structure, there can be overlaps in their effects.

Q: What are the most common mild side effects people experience with Afonilum SR?

A: According to official product information, commonly documented reactions primarily affect the nervous system and digestive tract. These include nausea, vomiting, headache, insomnia, tremor, dizziness, palpitations, and restlessness. The occurrence and severity of these reactions are often concentration-dependent, meaning they relate to the amount of medicine present in the bloodstream.

Q: What is a 'therapeutic window' and why is it important for Afonilum SR?

A: Theophylline is considered a Narrow Therapeutic Index (NTI) drug. This means there is a small margin between the concentration needed for effectiveness and the concentration that can cause serious side effects. For this reason, Therapeutic Drug Monitoring (TDM)—the careful measurement of blood levels—is often required during treatment to help maintain the concentration within the therapeutic range.

Q: Why do some people feel more 'jittery' on Afonilum SR than others?

A: Official information indicates that the rate at which the body processes theophylline (its clearance) can vary widely among individuals. Factors like age, smoking status, the presence of other medical conditions, and other medications can affect this clearance. These differences can result in higher or lower levels of the drug in the blood, leading to differing experiences of side effects such as tremor or restlessness.

Q: Is there a specific time of day that is best to take Afonilum SR?

A: The extended-release form is designed for a sustained effect and should be taken at the same time each day to help ensure continuous and stable blood levels of the medicine. The dosing schedule is individualized and frequently includes a dose taken in the morning.

Q: What should I do if my symptoms feel worse after starting Afonilum SR?

A: If breathing symptoms worsen, or if a person becomes severely short of breath, official warnings emphasize the need for immediate medical attention. Afonilum SR is used for long-term control of a condition, and worsening symptoms may signal a need for urgent reevaluation.

Q: Is there any research that suggests Afonilum SR also has anti-inflammatory properties?

A: Official product information describes theophylline’s mechanism as two-fold: it causes bronchodilation (muscle relaxation) and has a non-bronchodilator prophylactic effect. This second action, which suppresses the airway response to certain stimuli, is linked to the drug's influence on inflammatory signaling pathways, such as the activation of an enzyme called Histone Deacetylase 2 (HDAC2).

Q: How quickly does the effect of Afonilum SR wear off after missing a dose?

A: Due to its design as a sustained-release formulation, Afonilum SR is intended to provide a continuous effect over 12 to 24 hours. The active ingredient, theophylline, also has a relatively long half-life (the time it takes for half the drug to leave the system). This combination suggests the medicine remains in the system to provide ongoing management.

Q: Does Afonilum SR work better when taken with or without food?

A: Official information states that the medicine can be taken with or without food. However, taking the medicine with food may sometimes delay the time it takes for the drug to reach its peak concentration in the bloodstream. Consistency in the timing of the dose, regardless of food, is often emphasized.

Q: Can Afonilum SR be used by individuals with mild liver or kidney problems?

A: The body primarily clears theophylline through the liver. In individuals with liver impairment, the clearance is often significantly reduced, which increases the potential for the medicine to build up. In these cases, the dose often requires careful adjustment and frequent monitoring to minimize the risk of drug accumulation.

Q: What distinguishes Afonilum SR from drugs that work on different lung receptors?

A: Afonilum SR, through its active component theophylline, works primarily by inhibiting Phosphodiesterase (PDE) enzymes and acting as an Adenosine Receptor antagonist. This mechanism differs from other common bronchodilators, which may work by directly stimulating other receptor types (e.g., beta2-agonists).

Q: What is the scientific basis for how Afonilum SR improves breathing?

A: The scientific basis for improved breathing is theophylline's function as a bronchodilator. Its primary action is to inhibit PDE enzymes within the bronchial smooth muscle. This inhibition causes the muscles around the airways to relax and the bronchial tubes to widen, making breathing easier.

Q: Are there different brand names that contain the same active ingredient as Afonilum SR?

A: Yes, the active ingredient, theophylline (or its salt Choline Theophyllinate), is marketed and used internationally under various different brand names. Examples of other brand names include Elixophyllin, Theodur, and Uniphyl.

Q: Why do some patients need a higher dose of Afonilum SR than others?

A: Dosing is highly individualized because the rate at which the body clears the drug (clearance) varies widely based on factors such as age, weight, smoking status, and the presence of concurrent diseases. These factors determine the final dose needed to keep the medicine in the safe and effective range.

Q: What is the risk of having a serious side effect with Afonilum SR?

A: Regulatory warnings state that the frequency and severity of adverse reactions, including serious events like seizures and severe cardiac arrhythmias, are highly concentration-dependent. The risk increases significantly if the concentration of the medicine in the bloodstream rises above the recommended therapeutic range.

Q: Is it normal to feel slightly nauseous when first starting Afonilum SR?

A: Nausea and upset stomach are listed in the official adverse reactions profile as commonly documented side effects. Although they are not explicitly designated as a 'start-up' effect, these symptoms are sometimes reported by patients, particularly when beginning therapy with this type of medication.

Q: How does Afonilum SR affect the heart rate?

A: Theophylline can influence the function of the heart. Documented adverse reactions include palpitations, an increased or rapid heart rate, and potentially severe disturbances in the heart's rhythm, known as cardiac arrhythmias.

Q: Can consuming caffeine (coffee, tea, soda) affect the safety or effectiveness of Afonilum SR?

A: Official information indicates that consuming large amounts of foods and drinks high in caffeine may increase the side effects caused by theophylline. Since theophylline and caffeine are both chemically classified as methylxanthines, concomitant use may potentially raise the risk of experiencing adverse effects.

How should Afonilum SR be stored and disposed of?

Official Storage and Disposal Requirements

Requirement Area	Regulatory Statement
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protection	Keep the medication in a tightly closed, well-closed container. Protect from excess heat and excess moisture.
Child Safety	Store medication out of the sight and reach of children. Use a child-resistant closure.
Disposal Instructions	Do not flush this medication down the toilet or pour it down a drain. The preferred disposal method is a drug take-back program. If unavailable, mix the medicine with an unappealing substance (like used coffee grounds or dirt) and seal the mixture in a plastic bag before discarding in household trash.

Afonilum SR